KALTF - KALTF STOCK NEWS

Claritas Pharmaceuticals (OTC: KALTF) announced the expansion of its R-107 development program to target COVID-19 related sepsis following positive results in a large animal model. The study showed a significant reduction in mortality, demonstrating an 11% mortality rate in R-107 treated sheep, compared to 30% in the control group. Sepsis, a major complication of COVID-19, has a mortality rate of 30%-40% among affected patients. The findings support R-107's potential as a treatment option for high-risk COVID-19 patients with sepsis.

Kalytera Therapeutics has rebranded to Claritas Pharmaceuticals, signaling a renewed focus on developing R-107, a nitric oxide-releasing drug targeting vaccine-resistant COVID-19 and other viral infections. The company's new ticker symbol will be CLAS, pending approval from the TSX Venture Exchange. An annual and special meeting is set for June 17, 2021, to discuss corporate strategies and various shareholder votes, including the potential consolidation of common shares and approval for asset transfers related to the GVHD Program.

Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, KALTF) announced the successful completion of GLP genotoxicity studies for R-107, a therapy targeting vaccine-resistant COVID-19 and other viral diseases. Conducted at Covance Laboratories, the studies confirm R-107's safety, revealing no mutagenic activity or chromosomal damage. With FDA compliance achieved, Claritas plans to initiate Phase 1 clinical trials in Adelaide later this year. R-107, a nitric oxide-releasing prodrug, offers an innovative delivery method, enhancing therapeutic outcomes for patients.

Claritas Pharmaceuticals announces the appointment of Robert Farrell as Chairman of the Board following the resignations of Ronald Erickson and Robin Hutchison. This leadership transition is part of the company's effort to strengthen its expertise in nitric oxide therapy, particularly with the development of its proprietary drug, R-107. Farrell emphasizes the importance of assembling a world-class team to lead advancements in nitric oxide pharmacology, positioning Claritas to address significant unmet medical needs.

Claritas Pharmaceuticals has announced successful completion of toxicology studies of R-107 in canines, following positive results in rodents. Conducted by Covance Laboratories, these studies meet FDA requirements for advancing to Phase 1 clinical trials in humans. The studies evaluated R-107 at various dosages, confirming strong safety margins for human use. This drug, intended for COVID-19 and other viral infections, demonstrates promising plasma level correlations which may simplify dosing regimens. Claritas emphasizes the completion of these studies as a significant regulatory advancement.

Claritas Pharmaceuticals, Inc. (KALTF) has completed GLP toxicology studies of R-107, a potential treatment for COVID-19 and other viral diseases. Conducted at Covance Laboratories, the studies showed R-107 was well tolerated at doses significantly exceeding the planned therapeutic dose in humans, providing over a 10-fold safety margin. These findings support R-107's regulatory path for injectable formulations and mark a critical step toward initiating Phase 1 clinical trials, anticipated later this year in Adelaide, Australia. The studies also confirmed a linear relationship between plasma levels and dosages of R-107.

Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) has established a Scientific Advisory Board led by Dr. Garry J. Southan, a leading expert in nitric oxide therapeutics. This board aims to enhance the development of nitric oxide-based treatments for diseases with unmet medical needs. Dr. Southan, with a robust background in nitric oxide synthase and its inhibitors, brings significant expertise to the company. The leadership believes that Dr. Southan's guidance will be crucial in advancing their nitric oxide therapies, particularly R-107, towards clinical application.

Claritas Pharmaceuticals has appointed Professor Salvatore Cuzzocrea, Ph.D., to its Board, enhancing its expertise in nitric oxide therapeutics. His extensive background includes leadership roles at the University of Messina and over 759 publications. Cuzzocrea's experience with R-107, a nitric oxide-releasing compound, positions the company to advance treatments for COVID-19 and other viral infections. The appointment aims to leverage his knowledge for broad-spectrum antiviral therapies, potentially improving health outcomes amid significant viral threats.

Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) has initiated a development program for R-107, a proprietary nitric oxide-releasing compound. The new nasal spray aims to prevent viral infections, including vaccine-resistant COVID-19 and influenza. R-107 is designed to boost nitric oxide levels in the nasal cavities to combat invading viruses, potentially reducing the severity and spread of infections. Supported by Professor Salvatore Cuzzocrea, the company emphasizes that R-107 is not yet claimed to cure COVID-19.